Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer

Non-small cell lung cancer is recognized as the deadliest cancer across the globe. In some areas, it is more common in women than even breast and cervical cancer. Its rise, vaulted by smoking habits and increasing air pollution, has garnered much attention and resource in the medical field. The firs...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenxiao Jiang (Author), Guiqing Cai (Author), Peter Hu (Author), Yue Wang (Author)
Format: Book
Published: Elsevier, 2021-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8201e3885f3f42649a3d9af8a4a8c852
042 |a dc 
100 1 0 |a Wenxiao Jiang  |e author 
700 1 0 |a Guiqing Cai  |e author 
700 1 0 |a Peter Hu  |e author 
700 1 0 |a Yue Wang  |e author 
245 0 0 |a Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer 
260 |b Elsevier,   |c 2021-11-01T00:00:00Z. 
500 |a 2211-3835 
500 |a 10.1016/j.apsb.2021.02.003 
520 |a Non-small cell lung cancer is recognized as the deadliest cancer across the globe. In some areas, it is more common in women than even breast and cervical cancer. Its rise, vaulted by smoking habits and increasing air pollution, has garnered much attention and resource in the medical field. The first lung cancer treatments were developed more than half a century ago. Unfortunately, many of the earlier chemotherapies often did more harm than good, especially when they were used to treat genetically unsuitable patients. With the introduction of personalized medicine, physicians are increasingly aware of when, how, and in whom, to use certain anti-cancer agents. Drugs such as tyrosine kinase inhibitors, anaplastic lymphoma kinase inhibitors, and monoclonal antibodies possess limited utility because they target specific oncogenic mutations, but other drugs that target mechanisms universal to all cancers do not. In this review, we discuss many of these non-oncogene-targeting anti-cancer agents including DNA replication inhibitors (i.e., alkylating agents and topoisomerase inhibitors) and cytoskeletal function inhibitors to highlight their application in the setting of personalized medicine as well as their limitations and resistance factors. 
546 |a EN 
690 |a Non-small cell lung cancer 
690 |a Personalized medicine 
690 |a Pharmacogenomics 
690 |a Pharmacogenetics 
690 |a Drug resistance 
690 |a Vinca alkaloids 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Acta Pharmaceutica Sinica B, Vol 11, Iss 11, Pp 3406-3416 (2021) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2211383521000423 
787 0 |n https://doaj.org/toc/2211-3835 
856 4 1 |u https://doaj.org/article/8201e3885f3f42649a3d9af8a4a8c852  |z Connect to this object online.